Linagliptin/Metformin Hydrochloride

Tier B — Position early

Boehringer Ingelheim International Gmbh

Originator

2012

First approval

Expiry (public)

$1.86B ▲

Peak sales

Small molecule

Type

Targets：DPP4, PRKAB1

Brand：Trajenta Duo, Jentadueto, Jentadueto Xr

Indications (approved)：Type 2 diabetes

Regional status

Approved

2012-01-30

Approved

2012-07-19

China

Approved

2017-03-22

Japan

Factories producing this API11

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

11 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Linagliptin/Metformin Hydrochloride?

Approved indications include: Type 2 diabetes.

When does the Linagliptin/Metformin Hydrochloride patent expire?

No public expiry year is available for Linagliptin/Metformin Hydrochloride yet; this page updates once verified.

How do I get a quote for Linagliptin/Metformin Hydrochloride intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29